Research Paper Volume 16, Issue 3 pp 2494—2516
Risk model based on genes regulating the response of tumor cells to T-cell-mediated killing in esophageal squamous cell carcinoma
Figure 7. Evaluation of clinical immunotherapy responses and drug sensitivity (A) TIDE analysis forecasts the proportion of responsive patients to immunotherapy in the high- and low-risk groups stratified by the prognostic model. (B) SubMap analysis unveiled significant divergence in anti-PD-1 immunotherapy response between the high-risk and low-risk groups. (C) Proportions of neoadjuvant chemotherapy response between high-risk and low-risk patient groups in the GSE104958 data set. (D–I) Treatment response rates to six chemotherapy agents based on drug sensitivity scores.